Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3749151 | 0.92 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL3748347 | 0.92 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL3740594 | 0.86 | TACR3 (0.43) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL3736120 | 0.86 | TACR3 (0.47) | — | |
| SCHEMBL15433960 | 0.77 | SLC6A2 (0.77) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL1289614 | 0.77 | SLC6A2 (0.77) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL9993370 | 0.77 | SLC6A2 (0.77) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL12067203 | 0.77 | SLC6A2 (0.77) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL2480492 | 0.76 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL13835445 | 0.76 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834008-B2 | neurokinin receptor 3 (NK3) antagonists; psychological disorders, inflammatory bowel disease, asthma, ischemia, Parkinson's disease; e.g. (1S,2R)-2-(4-Acetylamino-4-phenyl-piperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)-cyclopropanecarboxylic acid, benzyl-methyl-amide | H. LUNDBECK A/S (DK) | 2010-11-16 | — | — | US | disclosed |
| US-20060281746-A1 | Cyclopropyl derivatives as nk3 receptor antagonists | H. LUNDBECK A/S (DK) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281746-A1 | Cyclopropyl derivatives as nk3 receptor antagonists | TACR2, SLC6A3, TACR1 | SLC6A2 141/4885SLC6A4 153/4885SLC6A3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.